See more : New Best Wire Industrial Co.,Ltd (5013.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of MERCK Kommanditgesellschaft auf Aktien (MKGAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MERCK Kommanditgesellschaft auf Aktien, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Uniserve Communications Corporation (USSHF) Income Statement Analysis – Financial Results
- Genmab A/S (GMAB.CO) Income Statement Analysis – Financial Results
- Virginia Energy Resources Inc. (VEGYF) Income Statement Analysis – Financial Results
- PASSUR Aerospace, Inc. (PSSR) Income Statement Analysis – Financial Results
- Arbe Robotics Ltd. (ARBEW) Income Statement Analysis – Financial Results
MERCK Kommanditgesellschaft auf Aktien (MKGAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.merckgroup.com
About MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.99B | 22.23B | 19.69B | 17.53B | 16.15B | 14.84B | 15.33B | 15.02B | 12.84B | 11.50B | 11.10B | 11.17B | 10.28B | 9.29B | 7.75B | 7.56B | 7.06B | 6.26B | 5.87B | 5.34B | 7.20B | 7.40B |
| Cost of Revenue | 8.56B | 8.53B | 7.35B | 6.84B | 6.01B | 5.38B | 5.32B | 5.20B | 4.08B | 4.06B | 3.56B | 3.74B | 2.79B | 2.39B | 2.03B | 1.91B | 1.78B | 2.41B | 2.37B | 2.25B | 3.57B | 3.79B |
| Gross Profit | 12.44B | 13.71B | 12.34B | 10.70B | 10.15B | 9.45B | 10.01B | 9.82B | 8.77B | 7.44B | 7.54B | 7.44B | 7.49B | 6.91B | 5.72B | 5.65B | 5.28B | 3.84B | 3.50B | 3.09B | 3.63B | 3.61B |
| Gross Profit Ratio | 59.23% | 61.65% | 62.66% | 61.02% | 62.82% | 63.72% | 65.29% | 65.38% | 68.26% | 64.66% | 67.92% | 66.55% | 72.87% | 74.32% | 73.81% | 74.78% | 74.78% | 61.43% | 59.64% | 57.87% | 50.40% | 48.72% |
| Research & Development | 2.45B | 2.52B | 2.41B | 2.29B | 2.27B | 2.23B | 2.14B | 1.98B | 1.71B | 1.70B | 1.50B | 1.51B | 1.52B | 1.40B | 1.34B | 1.23B | 1.03B | 751.60M | 713.00M | 599.00M | 604.60M | 608.20M |
| General & Administrative | 1.39B | 1.31B | 1.24B | 1.19B | 1.15B | 993.00M | 930.00M | 854.00M | 719.90M | 608.60M | 562.40M | 552.20M | 1.01B | 478.20M | 424.90M | 446.20M | 444.70M | 386.70M | 354.70M | 329.20M | 412.40M | 468.00M |
| Selling & Marketing | 3.91B | 4.10B | 3.71B | 3.57B | 3.65B | 3.41B | 3.69B | 3.50B | 3.27B | 2.39B | 2.33B | 2.41B | 2.39B | 2.23B | 2.27B | 2.10B | 1.93B | 1.48B | 1.47B | 1.34B | 1.72B | 1.77B |
| SG&A | 5.31B | 5.40B | 4.96B | 4.76B | 4.81B | 4.40B | 4.62B | 4.35B | 3.99B | 2.99B | 2.89B | 2.96B | 3.40B | 2.71B | 2.70B | 2.54B | 2.38B | 1.86B | 1.82B | 1.67B | 2.13B | 2.24B |
| Other Expenses | 1.08B | 1.03B | 777.00M | 841.00M | 767.00M | 521.00M | 681.00M | 431.00M | 342.80M | 65.80M | 62.70M | 70.80M | 68.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.83B | 8.95B | 8.14B | 7.89B | 7.84B | 7.58B | 7.63B | 7.53B | 6.60B | 5.68B | 5.38B | 5.55B | 6.50B | 5.80B | 5.07B | 4.52B | 4.30B | 2.74B | 2.62B | 2.05B | 3.05B | 3.11B |
| Cost & Expenses | 17.38B | 17.48B | 15.49B | 14.72B | 13.85B | 12.97B | 12.95B | 12.73B | 10.68B | 9.74B | 8.94B | 9.28B | 9.29B | 8.19B | 7.10B | 6.43B | 6.08B | 5.15B | 4.99B | 4.30B | 6.62B | 6.90B |
| Interest Income | 121.00M | 71.00M | 46.00M | 39.00M | 66.00M | 55.00M | 26.00M | 20.00M | 32.00M | 30.60M | 30.10M | 35.60M | 57.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 272.00M | 235.00M | 272.00M | 387.00M | 476.00M | 339.00M | 348.00M | 342.00M | 348.80M | 222.70M | 248.00M | 301.20M | 319.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88B | 1.80B | 1.71B | 1.76B | 1.91B | 1.75B | 1.76B | 1.81B | 1.51B | 1.36B | 1.46B | 1.40B | 1.60B | 1.26B | 1.00B | 1.22B | 923.60M | 303.00M | 289.50M | 375.00M | 470.50M | 425.20M |
| EBITDA | 5.69B | 6.55B | 5.96B | 4.73B | 4.16B | 3.60B | 4.25B | 4.43B | 3.35B | 3.14B | 3.10B | 2.41B | 2.76B | 2.36B | 1.65B | 2.35B | 1.90B | 1.10B | 1.17B | 1.42B | 1.01B | 920.00M |
| EBITDA Ratio | 27.08% | 30.33% | 30.28% | 26.97% | 26.18% | 25.00% | 27.29% | 27.90% | 28.19% | 27.73% | 33.03% | 29.29% | 23.65% | 25.45% | 21.65% | 36.34% | 37.90% | 19.00% | 18.72% | 26.57% | 17.32% | 13.20% |
| Operating Income | 3.61B | 4.47B | 4.18B | 2.99B | 2.12B | 1.73B | 2.53B | 2.48B | 1.84B | 1.76B | 1.61B | 963.60M | 985.10M | 1.11B | 620.90M | 731.40M | 975.70M | 1.11B | 955.60M | 1.04B | 579.30M | 494.80M |
| Operating Income Ratio | 17.19% | 20.12% | 21.23% | 17.02% | 13.13% | 11.64% | 16.47% | 16.51% | 14.35% | 15.32% | 14.52% | 8.62% | 9.59% | 11.94% | 8.01% | 9.68% | 13.83% | 17.67% | 16.28% | 19.54% | 8.04% | 6.69% |
| Total Other Income/Expenses | -125.00M | -187.00M | -255.00M | -355.00M | -385.00M | -266.00M | -294.00M | -327.00M | -356.00M | -205.00M | -222.20M | -1.13B | -293.30M | -248.30M | -159.00M | -156.50M | -1.09B | 167.90M | 11.90M | -82.70M | -156.70M | -83.20M |
| Income Before Tax | 3.48B | 4.29B | 3.92B | 2.63B | 1.74B | 1.46B | 2.22B | 2.15B | 1.49B | 1.56B | 1.39B | 709.00M | 851.10M | 861.10M | 486.40M | 574.90M | -110.90M | 1.27B | 893.40M | 960.80M | 422.60M | 411.60M |
| Income Before Tax Ratio | 16.60% | 19.28% | 19.93% | 15.00% | 10.74% | 9.85% | 14.51% | 14.34% | 11.57% | 13.54% | 12.52% | 6.35% | 8.28% | 9.27% | 6.28% | 7.61% | -1.57% | 20.35% | 15.22% | 17.99% | 5.87% | 5.56% |
| Income Tax Expense | 650.00M | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M | -386.00M | 521.00M | 368.00M | 392.20M | 179.50M | 130.00M | 222.10M | 219.60M | 109.70M | 195.80M | -23.10M | 272.20M | 220.70M | 288.90M | 204.90M | 196.40M |
| Net Income | 2.82B | 3.33B | 3.06B | 1.99B | 1.32B | 3.37B | 2.61B | 1.63B | 1.12B | 1.16B | 1.20B | 566.70M | 606.50M | 641.50M | 376.70M | 379.10M | 3.52B | 1.00B | 672.70M | 671.90M | 217.70M | 215.20M |
| Net Income Ratio | 13.45% | 14.96% | 15.52% | 11.33% | 8.17% | 22.74% | 17.00% | 10.84% | 8.68% | 10.06% | 10.84% | 5.07% | 5.90% | 6.90% | 4.86% | 5.02% | 49.88% | 16.00% | 11.46% | 12.58% | 3.02% | 2.91% |
| EPS | 6.49 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| EPS Diluted | 6.50 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| Weighted Avg Shares Out | 435.13M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.40M | 434.78M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
| Weighted Avg Shares Out (Dil) | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.89M | 434.40M | 435.55M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
Merck KGaA (MKGAF) CEO Belén Garijo on Q1 2022 Results - Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - CEO of the Group Marcus Kuhnert - CFO Matthias Heinzel - CEO of Life...
Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year's World Conference on Lung Cancer, September 8-14, 2021, and the...
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix', the ‘Company') today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck...
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated...
Merck KGaA (MKGAF) CEO Stefan Oschmann on Q2 2020 Results - Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2020 Results Conference Call August 6, 2020 8:00 AM ET Company Participants Constantin Fest - IR Marcus Kuhnert - CFO Stefan Oschmann - CEO Conference Call Participants Matthew Weston - Crédit Suisse Peter Verdult - Citigroup...
Merck KGaA (OTCMKTS:MKGAF) vs. Amarin (OTCMKTS:AMRN) Head-To-Head Contrast
Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKGAF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and...
Source: https://incomestatements.info
Category: Stock Reports